ROCKing onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation

Kamran Rostami,1 Michael N Marsh,2,3 Matt W Johnson,2 Hamid Mohaghegh,4 Calvin Heal,5 Geoffrey Holmes,6 Arzu Ensari,7 David Aldulaimi,8 Brigitte Bancel,9 Gabrio Bassotti,10 Adrian Bateman,11 Gabriel Becheanu,12 Anna Bozzola,13 Antonio Carroccio,14 Carlo Catassi,15 Carolina Ciacci,16 Alexandra Ciobanu,12 Mihai Danciu,17 Mohammad H Derakhshan,18,19 Luca Elli,20 Stefano Ferrero,20 Michelangelo Fiorentino,21 Marilena Fiorino,14 Azita Ganji,22 Kamran Ghaffarzadehgan,23 James J Going,24 Saudit Ishaq,25 Alessandra Mandolesi,15 Sherly Mathews,1 Roxana Maxim,17 Chris J Mulder,26 Andra Neefjes-Borst,26 Marie Robert,27 Ilaria Russo,16 Mohammad Rostami-Nejad,4 Angelo Sidoni,10 Masoud Sotoudeh,19 Vincenzo Villanacci,13 Umberto Volta,21 Mohammad R Zali,4 Amitabh Srivastava28

ABSTRACT

Objectives Counting intraepithelial lymphocytes (IEL) is central to the histological diagnosis of coeliac disease (CD), but no definitive ‘normal’ IEL range has ever been published. In this multicentre study, receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off between normal and CD (Marsh III lesion) duodenal mucosa, based on IEL counts on >400 mucosal biopsy specimens.

Design The study was designed at the International Meeting on Digestive Pathology, Bucharest 2015. Investigators from 19 centres, eight countries of three continents, recruited 198 patients with Marsh III histology and 203 controls and used one agreed protocol to count IEL/100 enterocytes in well-oriented duodenal biopsies. Demographic and serological data were also collected.

Results The mean ages of CD and control groups were 45.5 (neonate to 82) and 38.3 (2–88) years. Mean IEL count was 54±18/100 enterocytes in CD and 13±8 in normal controls (p=0.0001). ROC analysis indicated an optimal cut-off point of 25 IEL/100 enterocytes, with 99% sensitivity, 92% specificity and 99.5% area under the curve. Other cut-offs between 20 and 40 IEL were less discriminatory. Additionally, there was a sufficiently high number of biopsies to explore IEL counts across the subclassification of the Marsh III lesion.

Conclusion Our ROC curve analyses demonstrate that for Marsh III lesions, a cut-off of 25 IEL/100 enterocytes optimises discrimination between normal control and CD biopsies. No differences in IEL counts were found between Marsh III a, b and c lesions. There was an indication of a continuously graded dose–response by IEL to environmental (gluten) antigenic influence.

INTRODUCTION

Coeliac disease (CD) has a large spectrum of clinical and histological presentations. The accompanying structural changes in the upper small intestinal mucosa range through normal or near-normal to severe changes where partially reduced villi amalgamate into large, lozenge-shaped surface plateaus. The mucosa ‘flattens’, these markedly hypertrophic responses are triggered by lamina propria T cells under genetic control. Intraepithelial lymphocytes (IEL) lying within the epithelium, and surveying both lumen and lamina propria, are also implicated in this process, although their functions and prognostic value still remain somewhat undecided. An increased population of IEL has, for almost five decades, provided a sensitive histological pointer towards CD diagnosis, made more important over the years by the Marsh classification and its emphasis on the infiltrates in normal-looking, villus-bearing mucosa. CD is not the only intestinal condition associated with increased IEL counts, which has resulted in the view that a lymphocytosis characterising the milder Marsh I and II lesions can be dismissed as ‘non-specific’. To overcome this impasse, a recent paper dealing with the differential diagnosis of these lymphocytic infiltrates was recently published by the Bucharest Consensus and collectively defined as microscopic enteritis.

The Bucharest Consensus was primarily concerned with subtle submicroscopic changes and IEL in coeliac and non-coeliac mucosae. However, despite the numerous papers written on this subject, we were concerned that the literature lacks a definitive cut-off point to confirm the diagnosis. First, there is no universal definition for a ‘normal’ IEL range, and so this makes it difficult to define a specific point of departure favouring a histological diagnosis of CD.
**Significance of this study**

**What is already known on this subject?**
- Increased population of intraepithelial lymphocytes (IEL) provides a sensitive histological pointer towards coeliac disease (CD) diagnosis.
- IEL lying within the epithelium, and surveying both lumen and lamina propria, are implicated in disease activity, but their functions and prognostic value still remain somewhat undecided.
- Submicroscopic changes of epithelial cells and the differential diagnosis of lymphocytic infiltrates were collectively defined as microscopic enteritis.

**What are the new findings?**
- We show that an effective cut-off can be obtained with receiver operating characteristic curve analysis, which substantially reduces the overlap between CD and normal controls.
- We confirm that counting of IEL performed on H&E-stained material provides optimal results, compared with CD3/γ8 immunostained sections.
- We have graphically represented the cumulative totals of IEL across all our biopsies, revealing a continuous ‘dose–response’ curve reflective of the IEL response to luminal antigen, rather than a biphasic or clonal response that might have distinguished controls from coeliac. This has never been demonstrated before.
- Finally, with a reliable, large sample, our differential counts revealed no differences between Marsh III a, b and c, indicating that the subdivision of Marsh III has no practical value.

**How might it impact on clinical practice in the foreseeable future?**
- Our differential IEL counts offer unexpected insights into mucosal interpretation that will improve diagnostic accuracy. These include bringing clarity to the IEL’s implications in CD histogenesis, subdivision of Marsh III, assessing the diagnostic role of immunohistochemistry and proposing an effective cut-off to separate disease control from CD.

The earliest paper used very thick H&E sections (5–7 µm) which are not ideal for making accurate counts, while suggesting that IEL populations are normally distributed. An extremely high cut-off of 40 IEL/100 enterocytes was proposed. Various immunohistochemical approaches have also been deployed since that time, but never incorporated into routine practice. Moreover, despite its apparent sophistication and derived insights, the use of immunohistochemistry can be time consuming, requiring additional laboratory techniques and technologies which, when services are substantially reduced the overlap between CD and normal controls.

**METHODS AND MATERIALS**

This case–control study was designed during the International Meeting on Digestive Pathology held in Bucharest, November 2015. It is a multicentred international study involving eight countries, comprising 19 laboratories, each of which provided histological reviews of 10 patients with CD and 10 disease control (DC) patients. The 19 participating centres provided their data from Europe, Middle East and America, which included Ancona, Bologna, Brescia, Salerno, Perugia, Milan and Sciaccia (Italy); Dudley, Glasgow, Luton and Milton Keynes (UK); Mashhad and Tehran (Iran); Amsterdam (The Netherlands); Ankara (Turkey); Bucharest and Iasi (Romania); Lyon (France) and Boston (USA).

In total, this provided assessments on 401 biopsy specimens and IEL counts on 198 patients with CD (142 (71.7%) women and 56 (28.3%) men) and 203 DC patients (120 (59.1%) women and 83 (40.9%) men). The CD and DC biopsies were selected if they had 4–6 well-oriented tissue samples to allow evaluation of villous/crypt ratio and the number and distribution of the lymphocytes. The number of IEL/100 epithelial cell nuclei was counted in a continuous manner, leaving out the crypt openings. Each laboratory reanalysed the quality of cases before sending the results centrally for consolidation and review. Prominent clinical features relevant to each group are listed (table 1). The inclusion criteria for recruitment were positive coeliac serology and typical histological abnormalities consistent with Marsh III changes.

The subjects with DC were selected from patients with iron deficiency and a negative coeliac serology. Exclusion criteria for DC included active infections, for example, *Helicobacter pylori* or bacterial overgrowth, non-steroidal anti-inflammatory drugs use, food allergy or any other small bowel disorders. In this retrospective study, H&E-stained 4–5 µm thick sections cut from formalin-fixed paraffin-embedded archival material were used in 162 cases. Some centres additionally employed CD3 immunohistochemistry, involving 36 patients, using commercially available anti-CD3 antibodies. The CD3 antibody clone and vendor and dilutions were different in each centre.

The project aimed to measure the number of IEL/100 enterocytes in well-oriented duodenal biopsies from patients with untreated CD compared with a corresponding number of DC biopsies.
subjects. A definitive diagnosis of CD was defined as those patients demonstrating Marsh III histological abnormalities with positive serology in line with the current and previous guidelines, whereas those with seronegative Marsh III lesions were excluded. A multi-institutional collaborative effort to define optimal cut-offs to diagnose CD in patients with milder mucosal changes (Marsh I–II) is being planned as follow-up to our current study.

**Ethical considerations**

This study involved re-scoring of archived histology slides, and all identifiable medical information was removed and all analyses were performed using anonymised data. The data collection was in line with good clinical practice policies with approval by research and development/audit departments of countries involved. The study was also fully approved by the ethical committee of Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Science, Tehran under the following ethical number: IR.SBMU.RIGLD.REC.1395.87.

**Statistical analysis**

Data are reported as mean (±SD) for continuous variables and as proportion for categorical variables. Comparisons were performed using the Student’s t-test or χ² test, as appropriate. Receiver operating characteristic (ROC) curves were used to evaluate sensitivity and specificity for different cut-off levels of IEL/100 in detecting CD. Statistical significance was set at α=0.05.

**RESULTS**

The mean ages of DC and CD groups were 38.3 (range: 2–88) and 45.5 years (range: newborn to 82), respectively, of which 59% and 71% were women. The mean IEL count was 54±18/100 enterocytes for CD compared with 13±8 for DC (p=0.0001). We present data (figure 1) from IEL counts based on the largest series of intestinal biopsies analysed to date, obtained from eight countries across three continents (North America, Europe and Middle East). In total, 401 specimens were studied, of which 198 came from well-defined patients with CD who were either endomysial antibodies (EMA) or tissue transglutaminase antibodies (tTG) antibody positive (table 1). Of the 198 patients with CD with Marsh III, 27% had iron deficiency anaemia, 13% abdominal pain, 34% diarrhoea and 6% weight loss (table 1).

The mean±SD for the DC was 13±7 IEL/100 enterocyte nuclei (95% CIs 1–27). The normality of the variable was assessed visually using a histogram/assessed using a Shapiro-Wilk test which confirmed that the data are skewed to the right and distinctly non-normal. The mean IEL count for CD was 54±18 (95% confidence limits 19–54), differing significantly from CD (p<0.0001). The ‘normalised’ CD mean was 51±14 (95% confidence limits 24–78). Overall, using numerical data, CD and DC biopsies showed an overlap of 56 biopsies comprising 14% of the total specimens analysed. More interestingly with log-transformation, the distributions were ‘tightened’, so that the gross overlap was then reduced to 1%, or 38 biopsies. The literature presents a variety of optimum cut-off points ranging between 20 and 40 IEL/100 enterocyte nuclei, as criteria in the diagnosis of CD (table 2). However, these levels were, surprisingly, determined from means and SD originating from some extremely small groups. In this study, we had the advantage of large numbers of CD and DC biopsies which were further evaluated through ROC curve analysis (figure 2). This offered an optimal cut-off point of 25 IEL/100 enterocytes, with a sensitivity of 0.990 and specificity of 0.931, although the specificity was now reduced to 0.081. This led to an 18.2% false-positive result, which would have represented 37 DC biopsies being incorrectly labelled as ‘possible CD’. Since the actual numbers of cases misdiagnosed at these outer IEL counts are very high, their inaccuracy as histopathological guidelines is clearly evident.

Both the numerical overlapping (figure 1) and the shape of the ROC curve (figure 2) confirmed our previously published assertion1 that IEL do not represent bimodally distributed populations. This was further confirmed by our cumulative IEL count, biopsy-on-biopsy (figure 3), indicative of a graded dose-response by IEL to environmental (gluten) antigenic influence.19

By taking 25 IEL/100 enterocytes as the optimal distinguishing value, a significant reduction was seen in the numerical overlap between patients with CD and DC patients (figure 1). In most previously published series, this overlap has not previously received much in-depth analysis. Given that the IEL are not bimodally distributed, any proposed cut-off between DC and CD biopsies should be seen as arbitrary. In this series, the ROC-based overlap consisted of 3 CD women as false negatives and 12 DC as false positives. Although we had expected to have
Table 2  Summary of literature on IEL counts

<table>
<thead>
<tr>
<th>Study</th>
<th>Methods</th>
<th>Number of biopsies</th>
<th>Upper range</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferguson and Murray et al</td>
<td>H&amp;E staining, IEL/100 enterocytes, 7 µm sections</td>
<td>40</td>
<td>40</td>
<td>Used controls, coeliac &amp; autoimmune conditions, incorrect about normally distributed IEL, highest IEL count recorded: 155</td>
</tr>
<tr>
<td>Batman et al</td>
<td>H&amp;E staining, 5 µm sections</td>
<td>8</td>
<td>33</td>
<td>Study of HIV enteropathy</td>
</tr>
<tr>
<td>Hayat et al</td>
<td>H&amp;E staining, 4 µm sections</td>
<td>20</td>
<td>25</td>
<td>Counts made on uninterrupted length of epithelium &gt;500 EC, controls defined only by a normal sugar permeability</td>
</tr>
<tr>
<td>Mahadeva et al</td>
<td>H&amp;E staining, 3 µm sections</td>
<td>29</td>
<td>22</td>
<td>Major interest in normal villi with IEL infiltrate. Really difficult to infer group numbers here</td>
</tr>
<tr>
<td>Kakar et al</td>
<td>H&amp;E staining</td>
<td>12</td>
<td>29</td>
<td>Interest in normal villi with IEL infiltrates</td>
</tr>
<tr>
<td>Veress et al</td>
<td>H&amp;E staining, 3 µm CD3+</td>
<td>64</td>
<td>H&amp;E: 20 CD3+: 5–9</td>
<td>In H&amp;E sections, if IEL to EC ratio &gt;5:1, do CD3 count</td>
</tr>
<tr>
<td>Biagi et al</td>
<td>H&amp;E staining</td>
<td>17</td>
<td>45</td>
<td>Major interest in promoting villous tip counts</td>
</tr>
<tr>
<td>Lähdeaho et al</td>
<td>H&amp;E staining</td>
<td>76</td>
<td>26</td>
<td>No reasons given for this cut-off value: referred to Ferguson and Murray and Kuitunen et al who give no reference range</td>
</tr>
<tr>
<td>Nasseni-Moghaddam et al</td>
<td>H&amp;E staining, CD45+ cells</td>
<td>46</td>
<td>H&amp;E: 46 CD45+: 47</td>
<td>Establishing normal criteria by histology and immunocytoLOGY</td>
</tr>
<tr>
<td>Siriweera et al</td>
<td>H&amp;E staining</td>
<td>75</td>
<td>8</td>
<td>Retrospective study on 38 control and 37 coeliac specimens. Inexplicably small upper ranges for both groups</td>
</tr>
</tbody>
</table>

Notes: Here are tabulated some of the principal papers concerned with IEL counts in normal and diseased intestinal mucosa. Once identified in this way, it comes as a surprise that our perceptions of normality and of the accepted distinctions between normal and abnormal are so precariously based. Furthermore, the emphasis in some papers has been on the abnormal (HIV enteropathy), or with reference to a specific aspect (such as villus tip IEL), whereas in others, the actual numbers of patients are unclear, or a worked mean IEL±SD is not given. The very small size of some of the groups analysed should also be noted, since that has a major impact on the statistical ranges and confidence limits offered as diagnostic (with permission from Marsh & Heal.22,28,29 EC, epithelial cells; IEL, intraepithelial lymphocytes.

![Figure 2](image_url)  
**Figure 2**  The receiver operating characteristic (ROC) curve for all 401 biopsies employed in this study is shown here. If there had been no relationship between the two samples, the curve would have followed the diagonal line. Our ROC graph shows considerable between-group homogeneity, the area under the curve being 99.5%. However, the sensitivity axis does not pass through the upper-left corner, indicative of the overlap which is further examined in detail elsewhere.

![Figure 3](image_url)  
**Figure 3**  The cumulative IEL count, biopsy-on-biopsy, is illustrated in this diagram. The curve does not reach 401 on account of the overlapping counts between CD and DC mucosae, the overlap between biopsies being indicated by the two vertical parallel lines. The shape of the curve resembles a dose–response (to luminal antigen) and clearly demonstrates the absence of any bimodality between the two IEL populations. CD, coeliac disease; DC, disease control; IEL, intraepithelial lymphocytes.

seen an increase in IEL counts in eastern biopsies, this impression was not borne out in practice (figure 4).

There were significant differences in the results between the UK and Romania (p=0.011) and between Italy and Romania (p<0.0001). We did not pursue these correlations since the results were not significantly different (table 3).

Six groups submitted their counts as CD3+ totals, allowing the possibility of determining percentage counts for each Marsh III subdivision. Again, no differences were found (table 3) with the arithmetic mean, being 63 immunolabelled cells/100 enterocyte nuclei.

**DISCUSSION**

The results of this multicentre study across three continents indicated that: (1) the optimal cut-off point between CD and DC mucosae was 25 IEL/100 enterocyte nuclei, (2) there was no substantial difference in IEL counts from countries across the lesion and two others graded biopsies as a+b or b+c or even a+b+c. The IEL populations between these three groupings, however, were not significantly different (table 3).

![Image](image_url)
Coeliac disease

In contrast, a number of later studies, such as those of Ferguson and Murray, have also highlighted the value of assessing IEL in the diagnosis of CD. Ferguson and Murray introduced a grading system for the assessment of IEL, which was based on a subjective evaluation of the density of IEL. However, this approach was later found to be subjective and not reproducible, and it was not until the introduction of automated methods for the enumeration of IEL that the question of a cut-off, and how to locate it, was addressed.

Figure 4  This diagram illustrates the individual measurements from biopsies sampled across the Western hemisphere (USA, UK, France (FR), Netherlands (NL), Italy (ITAL), Romania (ROM), Turkey (TURK) and Iran). Bars reflect mean±SD for disease control (open circles) and coeliac disease (closed circles). The two sets of horizontal dotted lines indicate the overall mean±SD for the two groups of biopsies studied. IEL, intraepithelial lymphocytes.

Table 3 Breakdown of Marsh III mucosal lesions

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Biopsies (n)</th>
<th>H&amp;E IEL (mean±SD)</th>
<th>Biopsies (n)</th>
<th>CD3+ IEL (mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ila</td>
<td>36</td>
<td>54±14</td>
<td>10</td>
<td>60±11</td>
</tr>
<tr>
<td>IIb</td>
<td>38</td>
<td>52±17</td>
<td>12</td>
<td>67±19</td>
</tr>
<tr>
<td>IIC</td>
<td>63</td>
<td>55±21</td>
<td>14</td>
<td>62±31</td>
</tr>
<tr>
<td>Total</td>
<td>137</td>
<td>54±18</td>
<td>36</td>
<td>63±23</td>
</tr>
</tbody>
</table>

Statistics: H&E: Ila vs IIb, p=0.91; Ila vs IIC, p=0.96; IIb vs IIC, p=0.96. CD3+: Ila vs IIb, p=0.84; Ila vs IIC, p=0.92; IIb vs IIC, p=0.98.

Note: The subclassification of the Marsh III lesion has, to our knowledge, never been subject to critical analysis despite its widespread adoption, as almost a ‘matter of faith’. Here we show that the IEL counts across each of these subdivisions reveal no statistical differences. This is most worrying, since the subdivisions were supposed to represent specific, detectable and progressively deteriorating pathologies during the terminal phases of mucosal flattening. Moreover, despite smaller numbers, no detectable differences in CD3+ IEL were detected between the Ila, b and c subdivisions of the specimens analysed, in parallel with other findings. The use of elevated IEL counts has, for several decades, facilitated the histological diagnosis of CD. The original study which

Table 3 Breakdown of Marsh III mucosal lesions

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Biopsies (n)</th>
<th>H&amp;E IEL (mean±SD)</th>
<th>Biopsies (n)</th>
<th>CD3+ IEL (mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ila</td>
<td>36</td>
<td>54±14</td>
<td>10</td>
<td>60±11</td>
</tr>
<tr>
<td>IIb</td>
<td>38</td>
<td>52±17</td>
<td>12</td>
<td>67±19</td>
</tr>
<tr>
<td>IIC</td>
<td>63</td>
<td>55±21</td>
<td>14</td>
<td>62±31</td>
</tr>
<tr>
<td>Total</td>
<td>137</td>
<td>54±18</td>
<td>36</td>
<td>63±23</td>
</tr>
</tbody>
</table>

Statistics: H&E: Ila vs IIb, p=0.91; Ila vs IIC, p=0.96; IIb vs IIC, p=0.96. CD3+: Ila vs IIb, p=0.84; Ila vs IIC, p=0.92; IIb vs IIC, p=0.98.

Note: The subclassification of the Marsh III lesion has, to our knowledge, never been subject to critical analysis despite its widespread adoption, as almost a ‘matter of faith’. Here we show that the IEL counts across each of these subdivisions reveal no statistical differences. This is most worrying, since the subdivisions were supposed to represent specific, detectable and progressively deteriorating pathologies during the terminal phases of mucosal flattening. Moreover, despite smaller numbers, no detectable differences in CD3+ IEL were detected between the Ila, b and c subdivisions of the specimens analysed, in parallel with other findings. The use of elevated IEL counts has, for several decades, facilitated the histological diagnosis of CD. The original study which
comparison with our results (with 12 disease controls and 3 coeliac misdiagnosed), the values given in the literature fare badly. The important point to remember is that any cut-off is an arbitrarily fixed point. Nevertheless, given the large numbers of specimens examined in this study, together with their respective IEL populations, the results of our analysis probably represent the best result achievable and hence the most effective cut-off level of 25 IEL on H&E-stained sections for working practice.

However, in another recent publication, IEL counts were accumulated from the preceding 40-year literature, yielding 607 separate data points. In combining H&E-derived IEL counts from both studies (giving a total of 255 CD and 271 DC biopsies), ROC curve analysis provided an optimal cut-off of 26 IEL with 95.81% of the combined sample correctly identified. Marsh and Heal also found that separate ROC curve analyses for CD3+, and γ+δ+ IEL counts yielded less satisfactory cut-off points. Therefore, their results are consistent with the current Bucharest conclusion that H&E-derived IEL counts are adequate for its purpose. These are extremely interesting new insights and of great help to routine histopathologists in being reassured that immunohistochemistry does not offer improved diagnostic certainty.

IEL populations represent graded intestinal responses to antigenic challenge. This has been experimentally demonstrated in treated patients after gluten challenge. Here we have again confirmed and revealed the dose–response curve to gluten across all the specimens studied (figure 3). On inspecting our data, we were a little surprised that IEL counts did not increase across the globe from America to the near Middle East (figure 4), which we had suspected.

The statistical differences that were demonstrable are probably of little significance and were not evaluated further. It is, however, noteworthy that the IEL count is dependent on a surprisingly large number of internal and external factors including age, genetic background, ethnicity, geo-cultural factors, diet, food sensitivities, parasites, chronic liver disease, infections, drugs, the maternal and local intestinal microbiomes, and recent travel.

The large numbers of biopsies employed in this work helped to reveal the extent to which false-negative and false-positive misdiagnoses are incurred. A histologically negative result for CD appears to have less impact, since the clinician can employ additional assessments including Human Leucocyte Antigen (HLA) typing, EMA, increased anti-tTG titres or even deamidated gliadin assays to aid the diagnosis. A more difficult issue occurs when a normal biopsy is misclassified as CD, since there may be no additional pointers to avoid imposition of a lifelong gluten-free diet.

Finally, our study has cast more light on the subclassification of the Marsh stage III coeliac lesion that originated from Dutch studies and later taken over by Oberhuber et al in a review without citing the studies behind it. The subdivision of Marsh III was introduced to demonstrate a correlation between serology and degrees of mucosal abnormalities that led to first description of seronegative CD concept. Within our total sample, 132 biopsies were contributory, but we were surprised that nearly one-half (60, or 46%) were classified as Marsh IIIc, whereas only 38 (29%) were considered Marsh IIIb, and even less, 34 (25%), as Marsh IIIa. It should also be observed that we found no significant differences between the IEL populations within any of these subgroups (table 3). Although this subclassification was supposed to provide a ‘standardised procedure for mucosal classification’, no empirical measurements accompanied the modifications suggested, thus leaving this to subjective interpretation. A subsequent set of guidelines for pathologists, written by pathologists, offered micrographs of biopsies which did not correspond to those originally given. In a separate study of CD IEL and their immunohistochemical subtypes, no differences in the ‘lymphogram’ in terms of the subclassification of Marsh stage III mucosa could be found. That would be inconsistent with the original proposal that each subdivision supposedly represents a progressively greater degree of mucosal involvement and damage. Previous detailed morphological studies with transmission and scanning electronic microscopy have further degraded this subclassification by demonstrating their lack of relevance to mucosal architecture interpretation. A recent study from Australia which employed principal component and discriminant analyses found that defined algorithms could accurately distinguish the major Marsh grades, but were unable to discriminate between any of the so-called Marsh IIIa, b and c sublesions. Together, this growing body of information seems to indicate that attempted subclassifications of Marsh stage III lesions have no intrinsic status or value, and therefore would best be abandoned.

In that regard, six contributory groups within this study had already abandoned this subclassification, whereas two other groups classified their biopsies with multiple combinations of a+b+c, indicating the impossibility, if not gross frustration, of forcing one subclassification to fit into one or the other category. This might be an explanation for the anomalous finding that almost 50% of biopsies were classified as Marsh IIIc, with far less weight put on the other two subcategories. Clearly, if morphological, immunohistochemical or mathematically based analyses fail to reveal any major differences in the progressive degrees of tissue damage implied by this subclassification, then what value can emerge from its continued use? Equally strained is the growing habit of equating Marsh IIIa with so-called ‘partial villous atrophy’, Marsh IIIb with ‘subtotal villous atrophy’ and Marsh IIIc with ‘total villous atrophy’. Interestingly, in flat lesions, there is no evidence of an atrophic process, but only hypertrophic mucosal responses, and a striking absence of villi.

In summary, based on a large intercontinental study of IEL, involving over 400 biopsies, we have firmly established that a cut-off point of 25 IEL/100 enterocyte nuclei provides a very effective criterion for distinguishing CD Marsh III stage biopsies from DC tissues. No obvious trends in IEL counts were found in biopsies sampled from across the three continents. The CD IEL count is not normally distributed yet, as we have shown, this does not make any substantial difference to laboratory counting in the routine work of histopathologists. We found no differences when examining IEL populations throughout the three proposed subdivisions of the Marsh III lesion, suggesting that these subdivisions (a, b, c) are spurious, lacking any useful histopathological content, while offering no diagnostic or prognostic assistance whatsoever to the gastroenterologist.

Author affiliations
1Department of Gastroenterology and Pathology, Milton Keynes University Hospital, Milton Keynes, UK
2Department of Gastroenterology, Luton and Dunstable University Hospital, Luton, UK
3Wolfson College, University of Oxford, Oxford, UK
4Gastroenterology and Liver Diseases Research Centre, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, The Islamic Republic of Iran
5Centre for Biostatistics, Faculty of Biology, Academic Health Science Centre, University of Manchester, Manchester, UK
6Department of Gastroenterology, Royal Derby Hospital, Derby, UK
7Department of Pathology, Ankara University Medical School, Ankara, Turkey
8Department of Gastroenterology, Warwick Hospital, Warwick, UK
9Service de Pathologie, Centre de Biologie et Pathologie Groupe Hospitalier du Nord, Hospices Civils de Lyon, Lyon, France
10University of Perugia Medical School, Perugia, Italy
11Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
12Department of Pathology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Coeliac disease

1Institute of Pathology Spedali Civili, Brescia, Italy
2Internal Medicine and Pathology Unit, University of Palermo, Giovanni Paolo II Hospital, Sciacca, Italy
3Department of Pediatrics and Surgical Pathology, Università Politecnica delle Marche, Ancona, Italy
4Department of Medicine and Surgery, Scuola Medica Salesmatina, University of Salerno, Salerno, Italy
5Departments of Gastroenterology and Pathology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
6College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
7Digestive Disease Research Center, Tehran University Medical Science, Tehran, Iran
8Center for Prevention and Diagnosis of Coeliac Disease and Pathology Unit, Fondazione IRCCS Ca’ granda Ospedale Maggiore Policlinico, Milano, Italy
9Department of Medical and Surgical Sciences, University of Bologna and Diagnostic and Experimental, University of Bologna, Bologna, Italy
10Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
11Pathology Department, Razavi Hospital, Mashhad, Iran
12Department of Pathology, Southern General Hospital, Lanarkshire, UK
13Dudley group of Hospitals, Birmingham City University, Birmingham, UK
14Department of Hepatogastroenterology and Pathology, Free University Medical Centre, Amsterdam, The Netherlands
15Department of Pathology and Medicine, Yale University School of Medicine, New Haven, USA
16Department of Pathology, Brigham & Women’s Hospital, Boston, USA

Correction notice This article has been corrected since it published Online First. The affiliations for Sauid Ishaq, Masoud Sotoudeh and Stefano Ferrero have been updated.

Acknowledgements The authors would like to thank Coeliac UK for making this study accessible by funding the open access publication fee.

Contributors Forty-one pathologists and gastroenterologists participated in this study by contributing towards pathology and clinical data, discussion on study concept, statistical analysis and writing and revising the manuscript. The study was designed during the second consensus meeting incorporated in the International Course of Pathology in Bucharest. KR designed and coordinated the study, organised the second consensus meeting with help and support from GBE. He also collected the data and wrote the first draft of the manuscript. HM performed the first statistical analysis and contributed towards data interpretation. CH performed the second analysis and MNN rewrote the draft and revised the interpretation of data. MWJ and CH critically reviewed the manuscript and MW contributed with clinical and histology data. GBE provided data and co-ordinated the consensus meeting. MJD and HJG contributed with their data, critical revision, drafting and finalising the manuscript. ASr, AE, VV, UV, MV, MD, Aca, ANB, CCI, MRN and LE contributed in the conceptualisation and design of the study, data collection and critical revision of the manuscript. BB, GBE, ABS, CCA, ACi, SF, MIF, Mat, AG, KG, SI, AM, SM, RM, CJM, IR, ASi and MRR contributed with their pathology and clinical data and revision of the manuscript.

Competing interests None declared.

Ethics approval Research and development/audit departments of countries involved and the ethical committee of Research Institute for Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran under the following ethical number: IR.SBMU.RI.REC.1395.87.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s)) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


Gut: first published as 10.1136/gutjnl-2017-314297 on 11 September 2017. Downloaded from http://gut.bmj.com/ by guest on June 7, 2022. Protected by copyright.